Centessa Pharmaceuticals (CNTA) Total Non-Current Liabilities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Total Non-Current Liabilities data on file, last reported at $154.4 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 9.05% year-over-year to $154.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $154.4 million (up 9.05% YoY) and the FY2025 annual result came in at $160.6 million, down 8.34% from the prior year.
• Total Non-Current Liabilities fell to $154.4 million in Q1 2026 per CNTA's latest filing, from $160.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $175.2 million in Q4 2024 and bottomed at $101.0 million in Q2 2022.
• The 5-year median for Total Non-Current Liabilities is $118.5 million (2023), against an average of $128.8 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 317.49%; it then retreated 8.34% in 2025.
• Tracing CNTA's Total Non-Current Liabilities over 5 years: stood at $108.1 million in 2022, then grew by 14.64% to $124.0 million in 2023, then surged by 41.34% to $175.2 million in 2024, then declined by 8.34% to $160.6 million in 2025, then fell by 3.87% to $154.4 million in 2026.
• Per Business Quant, the three latest CNTA Total Non-Current Liabilities figures stand at $154.4 million (Q1 2026), $160.6 million (Q4 2025), and $146.7 million (Q3 2025).

Peer Comparison